Search
Displaying 51–60 of 662 for “retinitis clinical trial”
-
Antabuse Moves into Clinical Trial for People with RP
Research NewsResearchers believe the FDA-approved drug can reduce the hyperactivity of ganglion cells to improve vision.
-
PYC Doses First Patient in Clinical Trial of RNA Therapy for RP11 (PRPF31 Mutations)
Research NewsThe emerging RNA therapy is designed to boost expression of the PRPF31 protein
-
FDA Authorizes Clinical Trial for CRISPR/Cas9 Therapy for LCA 10
Research NewsEditas Medicine, a company developing gene-editing treatments, has received authorization from the US Food and Drug Administration to launch a clinical trial for its emerging CRISPR/Cas9 therapy for people with a mutation in the gene CEP290, which causes Leber congenital amaurosis 10 (LCA10). LCA causes severe vision loss or blindness at birth.
-
Interim Results Released for USH2A RNA Therapy Clinical Trial
Research NewsSuggestions of efficacy observed in 25 percent of participants receiving the treatment
-
ViGeneron Launches Clinical Trial of Gene Therapy for RP Caused by CNGA1 Mutations
Research NewsThe gene therapy is administered using a less-invasive intravitreal injection.
-
Ocugen to Launch Phase 3 Clinical Trial of Modifier Gene Therapy for RP
Research NewsThe emerging treatment is designed to work independent of the patient’s mutated gene.
-
Endogena Launches Clinical Trial of Therapy to Activate Stem Cells in RP Patients’ Retinas
Research NewsThe emerging treatment is gene-agnostic.
-
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
Research NewsMore details from the clinical trial will be reported at a later date
-
First Gene Therapy for Dry AMD Moves into Clinical Trial in UK
Research NewsGyroscope Therapeutics, a gene-therapy development company in the UK, has launched the first gene therapy clinical trial for the dry form of age-related macular degeneration (AMD).
-
jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP
Research NewsKnown as retinal progenitors, the company’s jCells® are designed to preserve photoreceptors in people with retinitis pigmentosa (RP) and other retinal diseases.
.png)
.png)
